Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Edvan de Queiroz Crusoé"'
Autor:
Carmino Antonio de Souza, Eduardo Magalhães Rego, Glaciano Nogueira Ribeiro, Silvia Maria Meira Magalhães, Celso Arrais Rodrigues da Silva, Leny Nascimento da Motta Passos, Dimas Tadeu Covas, Renato Sampaio Tavares, Vania T.de Moraes Hungria, Edvan de Queiroz Crusoé, José Francisco Comenalli Marques, Jr, Carlos Sérgio Chiattone, Dante Langhi, Junior, Jorge Vaz Pinto Neto, Violete Petitto Laforga, Angelo Maiolino
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss 3, Pp 219-220 (2024)
Externí odkaz:
https://doaj.org/article/e97df697154a44868843088db6a827e1
Autor:
Diego Lopes Paim Miranda, Alini Maria Orathes Ponte Silva, David Pereira Ferreira, Laís Teixeira da Silva, Liliane Lins-Kusterer, Edvan de Queiroz Crusoé, Marianna Batista Vieira Lima, Marco Aurélio Salvino
Publikováno v:
São Paulo Medical Journal, Vol 142, Iss 4 (2024)
ABSTRACT BACKGROUND: There are several illness-specific cultural and system-based barriers to palliative care (PC) integration and end-of-life (EOL) care in the field of oncohematology. OBJECTIVES: This study aimed to investigate the variability in t
Externí odkaz:
https://doaj.org/article/89c50eb27d264fa1b830c3c98aff50f0
Autor:
Gabriel Brayan Gutiérrez-Peredo, José César Batista Oliveira Filho, Iris Montaño-Castellón, Andrea Jimena Gutiérrez-Peredo, Edvan de Queiroz Crusoé, Dimitri Gusmao-Flores
Publikováno v:
BMC Nephrology, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background Monoclonal gammopathy of renal significance (MGRS) encompasses a heterogeneous group of kidney diseases in which a monoclonal immunoglobulin secreted by a clone of B cells or plasma cells causes kidney damage without meeting the h
Externí odkaz:
https://doaj.org/article/05017c25524e47c3af9ffe2282672395
Autor:
Angelo Maiolino, Edvan de Queiroz Crusoé, Gracia Aparecida Martinez, Walter Moisés Tobias Braga, Danielle Leão Cordeiro de Farias, Rosane Isabel Bittencourt, Jorge Vaz Pinto Neto, Glaciano Nogueira Ribeiro, Wanderley Marques Bernardo, Luca Tristão, Roberto J.P. Magalhaes, Vânia Tietsche de Moraes Hungria
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 44, Iss 3, Pp 410-418 (2022)
Externí odkaz:
https://doaj.org/article/9f41cd13c63d40d798d0c920b56d95f3
Autor:
Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Angelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Trufelli, Mariana Fernandez, Luciana Barreto Herriot
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss 4, Pp 417-423 (2021)
Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM). We report results of an early access protocol (EAP) of daratumumab monotherapy for
Externí odkaz:
https://doaj.org/article/1f1e7ed4750b4a32812d19e02ced92d7
Autor:
Vania Hungria, Marcia Garnica, Edvan de Queiroz Crusoé, Roberto Jose Pessoa de Magalhaes Filho, Gracia Martinez, Rosane Bittencourt, Danielle Leão Cordeiro de Farias, Walter Moises Braga, Jorge Vaz Pinto Neto, Glaciano Nogueira Ribeiro, Angelo Maiolino
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss 3, Pp 200-205 (2020)
Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access
Externí odkaz:
https://doaj.org/article/595552b747a447cca1c1bbbfc850f361
Autor:
Priscilla Cury de Camargo Cury, Fabiana Higashi, Flávia Fernandes Silva Zacchi, Renata Bacic Palhares, Adriana Alvares Quero, Ana Luiza Miranda Silva Dias, Edvan de Queiroz Crusoé, Vania Tietsche de Moraes Hungria
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss 2, Pp 159-163 (2020)
Background: Bone marrow angiogenesis is increased in multiple myeloma (MM) patients, prompting the rationale for using antiangiogenic drugs in the treatment of these patients. Objective: To assess angiogenesis in patients with MM at diagnosis and fol
Externí odkaz:
https://doaj.org/article/32f1b996d4044af194cc9e5d9584c08b
Autor:
Vania Tietsche de Moraes Hungria, Edvan de Queiroz Crusoé, Rosane Isabel Bittencourt, Angelo Maiolino, Roberto José Pessoa Magalhães, Jairo do Nascimento Sobrinho, Jorge Vaz Pinto, Ricardo Coutinho Fortes, Eloisa de Sá Moreira, Paula Yurie Tanaka
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 41, Iss 1, Pp 76-83 (2019)
The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhib
Externí odkaz:
https://doaj.org/article/ba28be5d368e447ea0952ff2b6de79ba
Autor:
Ana Luiza Miranda Silva Dias, Fabiana Higashi, Ana Lúcia M. Peres, Pricilla Cury, Edvan de Queiroz Crusoé, Vânia Tietsche de Moraes Hungria
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 40, Iss 1, Pp 30-36 (2018)
Introduction: The estimated involvement of the central nervous system in patients with multiple myeloma is rare at about 1%. The infiltration can be identified at the time multiple myeloma is diagnosed or during its progression. However, it is more c
Externí odkaz:
https://doaj.org/article/05b7ce73899b4191b46a67d49e322b91
Autor:
Marcia Garnica, Edvan De Queiroz Crusoe, Glaciano Ribeiro, Rosane Bittencourt, Roberto José Pessoa Magalhães, Karla Richter Zanella, Abrahão Elias Hallack Neto, Juliana Souza Lima, Caroline Bonamin Solo, Emmanuella Graciott Souza, Andre Magalhaes Fernandes, Angelo Maiolino, Vania Hungria
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 46, Iss 2, Pp 153-160 (2024)
Introduction: This study evaluated outcomes and risk factors for COVID-19 in 91 Brazilian multiple myeloma (MM) patients between April 2020 and January 2022. Results: Of the 91 MM patients diagnosed with COVID-19, 64% had comorbidities and 66% requir
Externí odkaz:
https://doaj.org/article/c9edf6eb43b64924bc1b945f53f5c868